Fresenius SE & Co. (FSNUY) Expected to Release Earnings on Wednesday

Fresenius SE & Co. (OTCMKTS:FSNUY) will likely be issuing its results before the market opens on Wednesday, November 4th. Analysts expect Fresenius SE & Co. to post earnings of $0.2156 per share and revenue of $6.51 billion for the quarter.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. On average, analysts expect Fresenius SE & Co. to post $1.04 EPS for the current fiscal year and $1.11 EPS for the next fiscal year.

Fresenius SE & Co. Stock Performance

FSNUY opened at $13.56 on Tuesday. The firm has a market cap of $30.55 billion, a P/E ratio of 12.99 and a beta of 0.60. Fresenius SE & Co. has a 52-week low of $10.33 and a 52-week high of $25.00. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The business’s fifty day moving average is $12.88 and its 200-day moving average is $12.87.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on FSNUY shares. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Citigroup reissued a “buy” rating on shares of Fresenius SE & Co. in a report on Wednesday, October 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Three investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Fresenius SE & Co. currently has a consensus rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.